NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application

Author's Avatar
May 17, 2022

SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for third quarter of its 2022 fiscal year with the Securities and Exchange Commission. This press release should be read in conjunction with the Company's Form 10-Q filed yesterday, May 16, 2022. The submission can be viewed at the SEC website at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0001379006/000141057822001688/nnvc-20220331x10q.htm .